Dactinomycin – Cancer Treatment

Dactinomycin, also known as Actinomycin D, is a highly potent cytotoxic antibiotic belonging to the actinomycin group, produced by the microorganism Streptomyces parvullus. It is one of the oldest and most thoroughly studied targeted chemotherapy agents, characterized by its profound antitumor activity.

The mechanism of action of dactinomycin is based on its ability to undergo highly selective intercalation into the minor groove of the DNA double helix between adjacent guanine-cytosine base pairs. By forming a stable complex with DNA, the drug creates a spatial obstruction for the progression of RNA polymerase, leading to selective inhibition of messenger RNA synthesis (transcription). At higher concentrations, dactinomycin also suppresses DNA synthesis and induces single-strand breaks in its structure.

As a cell cycle phase-nonspecific agent, it most effectively suppresses rapidly dividing malignant cells by blocking their proliferation and triggering apoptosis (programmed cell death) mechanisms, making it an indispensable component in the treatment of various rare and aggressive pediatric and adult malignancies.

Wikipedia page
Dactinomycin

Indications

Dactinomycin is used as part of comprehensive chemotherapy protocols for the treatment of the following conditions:

  • Wilms Tumor (Nephroblastoma): one of the primary components of combined therapy in pediatric patients.
  • Rhabdomyosarcoma: a malignant soft tissue tumor (usually in combination with vincristine and cyclophosphamide).
  • Trophoblastic Diseases: gestational choriocarcinoma (including forms resistant to methotrexate).
  • Ewing Sarcoma: a highly aggressive tumor of the bone and soft tissues.
  • Germ Cell Tumors: specific neoplasms of the testes and ovaries.
  • Local Treatment: may be used for regional perfusion in patients with melanoma and sarcomas of the limbs.

Dosage and administration

Dactinomycin therapy must be conducted strictly under the supervision of a specialized oncologist. The dose is calculated individually based on the patient's body weight or body surface area (BSA).

  • Standard Regimen: the dosage typically varies from 10 mcg/kg to 15 mcg/kg daily for 5 days every 4–6 weeks.
  • Route of Administration: the drug is administered exclusively intravenously. It is critical to avoid extravasation (leakage into surrounding tissues), as dactinomycin is a potent vesicant and causes severe tissue necrosis.
  • Calculation Specifics: when determining doses for patients with obesity or significant edema, calculations are based on "ideal" body weight to avoid severe overdose.
  • Monitoring: daily monitoring of blood counts and regular checks of renal and hepatic function are required throughout the entire treatment cycle.

The use of the drug is restricted in the following clinical situations:

  • Viral Infections: recent or current chickenpox or herpes zoster (risk of developing a fatal systemic disease).
  • Pregnancy and Lactation: the drug has proven high embryotoxicity and teratogenic effects.
  • Age: must be prescribed with extreme caution and in significantly reduced doses to infants under 12 months due to the high risk of systemic toxicity.
  • Hypersensitivity: individual intolerance to dactinomycin or any of the excipients.
  • Bone Marrow Suppression: significant leukopenia, anemia, or thrombocytopenia prior to the start of the course.

Dactinomycin has a pronounced toxicity profile that requires constant symptomatic support:

  • Hematology: deep myelosuppression (leukopenia, anemia, thrombocytopenia), with the peak typically occurring 7–10 days after administration.
  • Gastrointestinal: severe nausea and vomiting (occurring several hours after injection), pronounced stomatitis, heartburn, esophagitis, and proctitis.
  • Hepatobiliary System: risk of developing hepatic veno-occlusive disease (VOD), manifested by hepatomegaly, ascites, and elevated bilirubin levels.
  • Dermatology: complete alopecia, skin rash, and the specific "radiation recall" phenomenon (severe skin inflammation at sites of previous radiation therapy).

Frequently Asked Questions

Dactinomycin is an antitumor antibiotic derived from Streptomyces bacteria. Its mechanism of action involves intercalating into the DNA double helix and inhibiting RNA synthesis. This halts the division of cancer cells and leads to cell death. It is considered one of the most potent antineoplastic agents available.
This active substance is effective in treating specific pediatric and rare tumors. Key indications include Wilms' tumor (kidney cancer in children), rhabdomyosarcoma, Ewing's sarcoma, and trophoblastic diseases (choriocarcinoma). It is often used as part of combination chemotherapy regimens.
Dactinomycin is administered strictly intravenously. The substance is a potent vesicant, meaning it can cause severe tissue irritation. If the solution leaks into the surrounding tissue (extravasation), it can cause necrosis. Therefore, infusions must be performed with extreme caution by trained medical professionals.
Cosmegen is the original brand name. Generics (e.g., from Indian manufacturers like Dacmo by Celon) available on Unifarm contain the exact same active substance in a 0.5 mg (500 mcg) dosage. They are bioequivalent and offer the same therapeutic efficacy at a significantly lower price point.
The most common side effects include severe nausea and vomiting (which may occur hours after administration), hair loss, mouth sores (stomatitis), and bone marrow suppression. Dactinomycin can also increase skin sensitivity to radiation (radiation recall phenomenon) if the patient is also undergoing radiotherapy.
Dactinomycin in powder form for injection is light-sensitive. It should be stored in its original packaging, protected from light, at temperatures below 25°C. Reconstituted solutions should ideally be used immediately as they contain no preservatives.

List of medicines by active substance Dactinomycin

-26%
Dacilon 0.5 mg Celon
View
Celon

Dacilon

Dactinomycin
0.5 mg 1 vial
747₴ 1011₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00